Pulmonary hypertension in preterm infants with BPD represents a complex pathophysiological state characterized by elevated pulmonary artery pressures due to remodeling and constriction of the pulmonary vasculature. This increases the workload on the right ventricle, often culminating in heart failure, further jeopardizing survival and quality of life. Historically, treatment options have been limited and frequently associated with invasive procedures or systemic side effects. The advent of non-invasive nitric oxide delivery posits a transformative strategy by directly targeting the pulmonary vasculature, promoting vasodilation, and enhancing oxygen exchange at the alveolar-capillary interface.

Central to this innovation is the biochemistry of nitric oxide, a gaseous signaling molecule pivotal for vascular homeostasis. Nitric oxide diffuses rapidly across cell membranes and activates soluble guanylate cyclase in vascular smooth muscle cells, elevating cyclic guanosine monophosphate (cGMP) levels. This cascade triggers relaxation of smooth muscle cells, leading to vasodilation and improved blood flow. In the context of BPD-related pulmonary hypertension, these mechanisms counteract the pathological vasoconstriction and vascular remodeling that constrains pulmonary circulation, thereby alleviating right ventricular strain and improving systemic oxygenation.

The study meticulously evaluated the efficacy and safety profile of this non-invasive intervention in a multicenter cohort of preterm infants diagnosed with moderate to severe BPD complicated by pulmonary vascular disease. Employing sophisticated respiratory support devices capable of controlled nitric oxide delivery, the researchers observed significant reductions in pulmonary arterial pressures alongside improvements in oxygenation indices. Notably, the intervention was well tolerated, with no discernible adverse systemic effects or toxicity, underscoring its promise as a viable therapeutic alternative.

What sets this approach apart is the elimination of invasive catheterization or mechanical ventilation modifications traditionally used to administer vasodilators. Non-invasive nitric oxide delivery reduces infection risk, mechanical injury, and procedural complications, aligning with modern neonatal care principles that emphasize minimizing iatrogenic harm. Additionally, by facilitating outpatient management and potentially shortening hospital stays, this method optimizes healthcare resource utilization and aligns with family-centered care paradigms.

Beyond clinical outcomes, the research delves into the molecular adaptations within the pulmonary vasculature induced by nitric oxide therapy. Using advanced imaging and molecular assays, investigators documented decreased expression of proliferative and fibrotic markers in pulmonary endothelial cells, suggesting that nitric oxide not only improves hemodynamics but also modulates disease progression at a cellular level. This dual action opens avenues for modifying the natural history of pulmonary hypertension in BPD beyond symptomatic relief.

Despite these commendable advances, the study also highlights challenges requiring further exploration. Optimal dosing regimens, duration of therapy, and long-term developmental outcomes remain areas necessitating larger randomized controlled trials. Additionally, understanding patient-specific variables such as genetic predispositions and concomitant morbidities could refine patient selection and maximize therapeutic efficacy. Nonetheless, the foundational evidence presented provides a robust framework for integrating non-invasive nitric oxide therapy into clinical practice.

In the broader landscape of neonatal medicine, these findings resonate profoundly, given the rising incidence of premature births globally and the consequential surge in chronic lung disease prevalence. As survival rates improve, the imperative to address chronic complications like pulmonary hypertension becomes paramount. This research injects renewed vigor into the quest for safe, effective, and gentle therapies tailored to the fragile physiology of preterm infants.

Moreover, the principles underpinning this research might extend beyond neonatal populations. Pulmonary hypertension secondary to lung diseases is a pervasive challenge across age groups and conditions. Insights gained from the intricate interplay of nitric oxide signaling and pulmonary vascular pathology in infants could inspire novel therapeutic strategies for adults, especially those contraindicated for invasive interventions.

Behind the clinical findings is a testament to interdisciplinary collaboration melding neonatology, pulmonology, pharmacology, and bioengineering. The development of delivery devices capable of regulating nitric oxide dosages accurately and safely in small-volume respiratory circuits exemplifies translational science bridging bench-side discoveries to bedside innovations. Such synergy exemplifies future directions wherein technology and biology co-evolve to tackle unmet medical needs.

Importantly, the non-invasive nature of this therapy dovetails with ethical imperatives in neonatal care: minimizing distress and facilitating parent-infant bonding. By avoiding intubation or extensive respiratory manipulation, infants experience less procedural pain and stress, potentially affecting neurodevelopmental trajectories positively. This humane aspect, often overshadowed by clinical endpoints, enhances holistic care quality.

As this work gains traction within the clinical community, dissemination efforts must emphasize training on device operation, patient monitoring, and criteria for therapy initiation and cessation. Multidisciplinary teams, including neonatologists, respiratory therapists, and nursing staff, will need comprehensive protocols to ensure consistent application and safety.

In conclusion, the emergence of non-invasive nitric oxide therapy represents a monumental leap forward for preterm infants grappling with the dual burdens of bronchopulmonary dysplasia and pulmonary hypertension. This approach marries physiological insight with technological innovation, offering a pathway to improve survival, decrease complications, and enhance quality of life for one of the most fragile patient populations. As further research expands on these findings, the neonatology field stands at the cusp of redefining standards of care, bringing hope to families worldwide affected by prematurity’s long-term consequences.

Subject of Research: Non-invasive nitric oxide therapy for pulmonary hypertension and pulmonary vascular disease in preterm infants with bronchopulmonary dysplasia

Article Title: Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants

Article References:
Chandra, A., Rios, D.R., Dagle, D. et al. Non-invasive nitric oxide use for pulmonary hypertension and pulmonary vascular disease associated with bronchopulmonary dysplasia in preterm infants. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02687-w

Image Credits: AI Generated

DOI: 15 April 2026

Prematurity remains a leading cause of neonatal morbidity and mortality worldwide, often complicated by fragile respiratory mechanics and cardiovascular instability. Conventional imaging modalities, while informative, sometimes lack the sensitivity or immediacy necessary for fine-grained assessment and timely intervention. This context underscores the value of ultrasound techniques, which provide non-invasive, radiation-free, real-time evaluation of lung aeration patterns and cardiac deformation. The current pilot study serves as a critical inquiry into the interplay between lung pathology and ventricular mechanics, offering a nuanced perspective on how pulmonary compromise can modulate cardiac morphology in this vulnerable population.

Lung ultrasound score (LUS) has emerged in recent years as a robust, semi-quantitative tool capable of detecting degrees of pulmonary consolidation, interstitial syndromes, and atelectasis. This scoring system categorizes lung regions based on typical ultrasonographic patterns such as A-lines, B-lines, and consolidations, assigning points that cumulatively reflect the extent of lung aeration loss. Elevated LUS values signal aggravated respiratory compromise, often correlating with worse clinical outcomes. Notably, ultrasound’s bedside adaptability and high intra- and inter-observer reliability make LUS an increasingly favored metric in neonatal respiratory monitoring.

Simultaneously, the study delves into the left ventricular eccentricity index (LVEI), a measure derived from echocardiographic imaging that quantifies the deformation of the left ventricle shape – often observed as a septal shift or flattening under elevated right ventricular pressures. LVEI is calculated as the ratio of the length of the left ventricle parallel to the septum over the orthogonal dimension, hence quantifying how the interventricular septum deviates from its normal circular contour during both systole and diastole. This index is invaluable in detecting right ventricular pressure overload and pulmonary hypertension, conditions frequently intertwined with severe neonatal lung disease.

The investigative team meticulously enrolled preterm infants with established respiratory failure, conducting lung ultrasound and echocardiographic studies in a synchronized manner. Such synchronization is paramount, as cardiopulmonary dynamics rapidly fluctuate in neonates under respiratory distress, and correlating the LUS with LVEI indices required temporal precision. The researchers aimed to elucidate whether higher LUS, signifying worsening pulmonary aeration, directly corresponds to alterations in the left ventricular geometry as depicted by LVEI-s and LVEI-d.

Initial observations demonstrated a compelling association between the rising LUS and elevated LVEI values. Infants with more pronounced lung ultrasound abnormalities exhibited marked increases in eccentricity indices, indicating that severe pulmonary impairment correlates with significant distortion of left ventricular geometry during both systole and diastole. This biomechanical interplay suggests that increased pulmonary pressures and hypoxic pulmonary vasoconstriction in compromised lungs exert a tangible mechanical effect on cardiac structure — a phenomenon crucial for clinicians to recognize when evaluating respiratory failure in preterm neonates.

Furthermore, the study sheds light on the bidirectional relationship between pulmonary pathology and cardiac function. Some infants demonstrated elevated LVEI prior to episodes of clinical deterioration, hinting that LVEI might serve as a prognostic marker or early warning sign of worsening pulmonary hypertension and respiratory failure. This raises intriguing possibilities for integrating cardiac ultrasound indices into neonatal respiratory protocols, potentially enriching risk stratification and guiding timing for escalated intervention such as surfactant therapy or inhaled nitric oxide.

Importantly, the research team underscores methodological considerations concerning imaging acquisition and interpretation. The feasibility of consistent LUS and LVEI measurement in critically ill neonates was affirmed, emphasizing operator training and adherence to standardized protocols to mitigate variability. This operational rigor fortifies the study’s conclusions and supports wider adoption of these sonographic tools in neonatal care environments.

Intriguingly, the pathophysiological insights offered by coupling LUS and LVEI assessments point to an evolving understanding of how cardiopulmonary coupling governs neonatal health trajectories. Conventional siloed approaches assessing lungs and heart independently may overlook critical interdependencies that can significantly influence management. By highlighting the morphofunctional interrelation between lung aeration loss and ventricular eccentricity, this study encourages a shift toward integrated cardiopulmonary evaluation.

The study’s pilot nature warrants cautious extrapolation, but it lays a robust groundwork for larger, multicenter trials. Future research should aim to validate these findings in broader cohorts, explore longitudinal changes in LUS and LVEI during disease progression and recovery, and investigate how therapeutic interventions modulate these parameters. Such endeavors might unlock sophisticated diagnostic algorithms that combine lung and cardiac ultrasound data for real-time personalized care.

Clinicians and neonatologists stand to benefit profoundly from embracing these sonographic tools, as they bridge the gap between clinical observation and mechanistic understanding. The ability to non-invasively and dynamically assess how lung pathology translates into cardiac deformation heralds a new frontier in neonatal intensive care, ultimately aspiring to improve survival rates and neurodevelopmental outcomes for the most vulnerable infants.

Emerging technologies, including artificial intelligence-driven image analysis and portable ultrasound devices, will further amplify the utility and accessibility of LUS and LVEI measurement. By integrating automated quantification and cloud-based data sharing, neonatal care teams across diverse settings can access sophisticated cardiopulmonary insights hitherto reserved for specialized centers, democratizing advanced diagnostics and enabling earlier intervention.

Moreover, this study invites reflection on the broader implications of cardiopulmonary interactions across different age groups and disease entities. Insights gleaned from preterm infants may inform understanding of pediatric and adult conditions where respiratory failure coexists with cardiac remodeling, such as chronic obstructive pulmonary disease or pulmonary arterial hypertension. Such cross-disciplinary knowledge transfer exemplifies the transformative potential of focused neonatal research.

In summation, this trailblazing pilot study articulates a compelling narrative that lung ultrasound scoring and left ventricular eccentricity indices are interlinked biomarkers of respiratory failure in preterm neonates. Their combined use promises enhanced diagnostic acuity, refined prognostication, and tailored therapeutic pathways. As neonatal care advances, integrating multisystem ultrasound parameters may become the cornerstone of precision medicine for fragile infants, heralding improved outcomes and new horizons in infant healthcare.

Subject of Research: The association between lung ultrasound score (LUS) and left ventricular eccentricity index (LVEI) during end-systole and end-diastole in preterm infants experiencing respiratory failure.

Article Title: Lung ultrasound score and left ventricular eccentricity index in preterm infants with respiratory failure – a pilot study.

Article References:
Kelner, J., Hussain, N., Chicaiza, H. et al. Lung ultrasound score and left ventricular eccentricity index in preterm infants with respiratory failure – a pilot study. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02429-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41372-025-02429-4